Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
Authors:
- 18 January 2022
- journal article
- editorial
- Published by Elsevier in The Lancet Rheumatology
- Vol. 4 (4) , e241-e243
Abstract
No abstract availableFunding Information
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
This publication has 7 references indexed in Scilit:
- Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studiesThe Lancet Rheumatology, 2021
- Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccinationThe Lancet Rheumatology, 2021
- Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case SeriesAnnals of Internal Medicine, 2021
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19New England Journal of Medicine, 2021
- High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseasesAnnals of the Rheumatic Diseases, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical EvaluationJournal of Clinical Microbiology, 2021